TFFP Stock Overview A clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
TFF Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for TFF Pharmaceuticals Historical stock prices Current Share Price US$0.065 52 Week High US$11.00 52 Week Low US$0.061 Beta 1.06 1 Month Change -82.72% 3 Month Change -97.03% 1 Year Change -99.17% 3 Year Change -99.97% 5 Year Change -99.94% Change since IPO -99.95%
Recent News & Updates
TFF Pharmaceuticals, Inc.(NasdaqCM:TFFP) dropped from NASDAQ Composite Index Dec 13 Nasdaq Determines to Delist Common Stock of TFF Pharmaceuticals Dec 11
TFF Pharmaceuticals, Inc. Appoints Craig R. Jalbert as Chief Financial Officer
New major risk - Share price stability Aug 23
New major risk - Shareholder dilution Aug 21
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 16 See more updates
TFF Pharmaceuticals, Inc.(NasdaqCM:TFFP) dropped from NASDAQ Composite Index Dec 13 Nasdaq Determines to Delist Common Stock of TFF Pharmaceuticals Dec 11
TFF Pharmaceuticals, Inc. Appoints Craig R. Jalbert as Chief Financial Officer
New major risk - Share price stability Aug 23
New major risk - Shareholder dilution Aug 21
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 16
Consensus revenue estimates increase by 77% Aug 15
TFF Pharmaceuticals, Inc. Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection Aug 06
Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection Jun 24
Consensus revenue estimates decrease by 29%, EPS upgraded May 21 TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.055 million. May 18
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 16
Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection May 16 TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million. May 02
TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million. May 01
TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787505 million.
TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024 Apr 23
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions Apr 16
New major risk - Market cap size Apr 12 TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Apr 08
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 01
Consensus EPS estimates fall by 39% Mar 29
No longer forecast to breakeven Mar 29
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs Mar 28 TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million. Mar 22
TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million. Mar 21
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs Mar 20
New major risk - Share price stability Mar 05
TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference Jan 25
Forecast to breakeven in 2026 Dec 31
New minor risk - Profitability Dec 19
TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors Dec 14 TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $35 million. Nov 22
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 17
Consensus revenue estimates increase by 40% Nov 16
TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 21, 2023 Oct 05
Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board Sep 19
Consensus revenue estimates increase by 37% Aug 21
New major risk - Shareholder dilution Aug 18
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 16
Consensus revenue estimates increase by 21% May 26
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 13
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth? Apr 10
No longer forecast to breakeven Apr 08
No longer forecast to breakeven Apr 04
Key Executive recently bought US$132k worth of stock Mar 14
Consensus revenue estimates increase by 16% Feb 19
TFF Pharmaceuticals, Inc. Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer Feb 09
TFF Pharmaceuticals, Inc. Appoints Zamaneh Mikhak as Chief Medical Officer Jan 10
Forecast to breakeven in 2025 Dec 31
Key Executive recently bought US$53k worth of stock Dec 20 TFF Pharmaceuticals Announces Leadership Transition
Consensus revenue estimates increase by 98% Nov 21
Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.34 loss in 3Q 2021) Nov 17
High number of new and inexperienced directors Nov 16
Price target decreased to US$16.00 Nov 12
TFF Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 08
TFF Pharmaceuticals, Inc. Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program Nov 02
TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting Oct 12
Independent Director exercised options and sold US$72k worth of stock Oct 02
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans? Sep 27
TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting Sep 23
TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 07, 2022 Sep 22
TFF Pharmaceuticals, Inc. Announces Presentation of Patient Data with Voriconazole Inhalation Powder At the 15Th International Congress on Lung Transplantation Sep 10
TFF Pharma: The Potential Is Still Very Much Present Aug 29
Consensus revenue estimates fall by 84% Aug 18
No longer forecast to breakeven Aug 17
No longer forecast to breakeven Aug 15
Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.18 loss in 2Q 2021) Aug 12
TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways Aug 09
TFF Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 03
TFF Pharmaceuticals expands R&D operations with new Austin facility Jul 14
TFF Pharmaceuticals: A Highly Attractive Basket Of Options May 23 Shareholder Returns TFFP US Pharmaceuticals US Market 7D -77.6% 1.2% 0.2% 1Y -99.2% 1.4% 23.1%
See full shareholder returns
Return vs Market: TFFP underperformed the US Market which returned 27.6% over the past year.
Price Volatility Is TFFP's price volatile compared to industry and market? TFFP volatility TFFP Average Weekly Movement 34.0% Pharmaceuticals Industry Average Movement 10.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Stable Share Price: TFFP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TFFP's weekly volatility has increased from 23% to 34% over the past year.
About the Company TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
Show more TFF Pharmaceuticals, Inc. Fundamentals Summary How do TFF Pharmaceuticals's earnings and revenue compare to its market cap? TFFP fundamental statistics Market cap US$288.80k Earnings (TTM ) -US$18.52m Revenue (TTM ) US$1.16m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TFFP income statement (TTM ) Revenue US$1.16m Cost of Revenue US$10.70m Gross Profit -US$9.54m Other Expenses US$8.98m Earnings -US$18.52m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.17 Gross Margin -821.41% Net Profit Margin -1,595.04% Debt/Equity Ratio 0%
How did TFFP perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/15 14:57 End of Day Share Price 2024/12/12 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources TFF Pharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mayank Mamtani B. Riley Securities, Inc. Raghuram Selvaraju H.C. Wainwright & Co. Jason McCarthy Maxim Group
Show 1 more analysts 
